Blue Trust Inc. Has $27,000 Holdings in LifeStance Health Group, Inc. (NASDAQ:LFST)

Blue Trust Inc. grew its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 124.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,828 shares of the company’s stock after purchasing an additional 2,122 shares during the period. Blue Trust Inc.’s holdings in LifeStance Health Group were worth $27,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Townsquare Capital LLC purchased a new stake in shares of LifeStance Health Group in the 3rd quarter valued at approximately $73,000. R Squared Ltd acquired a new stake in LifeStance Health Group during the 4th quarter valued at $80,000. Entropy Technologies LP purchased a new stake in shares of LifeStance Health Group in the fourth quarter valued at $150,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of LifeStance Health Group by 31.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,105 shares of the company’s stock valued at $169,000 after purchasing an additional 5,767 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of LifeStance Health Group in the third quarter worth $176,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Price Performance

Shares of NASDAQ:LFST opened at $7.74 on Friday. The business has a fifty day simple moving average of $7.79 and a 200 day simple moving average of $7.21. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. LifeStance Health Group, Inc. has a 1 year low of $4.64 and a 1 year high of $9.20. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -29.77 and a beta of 1.28.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LFST. Barclays upped their price target on LifeStance Health Group from $6.00 to $7.00 and gave the company an “underweight” rating in a research report on Monday, November 11th. The Goldman Sachs Group upgraded LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.70.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.